Виокс

General characteristics. Structure:

Active ingredient: 12,5 mg or 25 mg of a rofekoksib.

Pharmacological properties:

Pharmacodynamics. Highly specific inhibits ЦОГ−2, slows down formation of antiinflammatory prostaglandins. In therapeutic concentration at the person does not influence activity ЦОГ−1.

Pharmacokinetics. After intake bioavailability — more than 90% is well soaked up from a GIT. Linkng with proteins of plasma — about 90%. Cmax is reached in 2 h. Is exposed to biotransformation in a liver with formation of six inactive metabolites.

It is removed preferential by kidneys (72% in the form of inactive metabolites, less than 1% — in not changed look) and with excrements (14% in not changed look). Plasma clearance — about 120 ml/min.

Indications to use:

Osteoarthritis (acute, chronic), stopping of a pain syndrome, treatment of primary dysmenorrhea.

Route of administration and doses:

Inside, during food or irrespective of meal. Osteoarthritis: an initial dose — 12,5 mg of 1 times a day, for achievement of effect increasing to the maximum dose — 25 mg.

Stopping of an acute pain and treatment of primary dysmenorrhea: an initial dose — 50 mg of 1 times a day, then — 25–50 mg of 1 times a day, the maximum daily dose — 50 mg.

Features of use:

Use during pregnancy. Contraindicated in the III trimester of pregnancy (perhaps premature fusion of Botallov Canal at a fruit). Perhaps in I and II trimesters of pregnancy if the expected effect of therapy at mother exceeds potential risk for a fruit (adequate and strictly controlled researches on use were not conducted). For the period of treatment it is necessary to stop breastfeeding.

With care apply at patients with the instruction on a peptic ulcer of a stomach and duodenum in the anamnesis, in the presence of hypostases, noncompensated heart failure, cirrhosis, at patients 65 years are more senior.

Against the background of the expressed renal or liver failure careful monitoring of function of kidneys/liver is necessary. At patients with dehydration carrying out a regidratation prior to treatment is desirable.

Side effects:

From a nervous system and sense bodys: dizziness, drowsiness, weakening of speed of thinking, confusion of consciousness, hallucination.

From cardiovascular system and blood (a hemopoiesis, a hemostasis): ≥ 2% — arterial hypertension, congestive heart failure.

From bodies of a GIT: ≥ 2% — heartburn, nausea, diarrhea, dyspepsia, discomfort in epigastric area; vomiting; in isolated cases — ulcerations of a mucous membrane of an oral cavity.

From urinogenital system: reversible depression of function of kidneys, including a renal failure.

Allergic reactions: Quincke's disease, itch, rash, small tortoiseshell.

Others: ≥ 2% — hypostasis of the lower extremities; ≥ 1% — increase in ALT and/or nuclear heating plant.

Interaction with other medicines:

Can increase concentration of a methotrexate in blood. At a concomitant use with warfarin the prothrombin time increases. Rifampicin reduces concentration in plasma by 50%.

Contraindications:

Hypersensitivity, including to other NPVS.

Overdose:

It is not described.

Storage conditions:

List B: to store at a temperature not above 25 °C. A period of validity - 24 months.

Issue conditions:

According to the recipe

Packaging:

Tablets of 12.5 mg; blister 7, box (box) 2; tablets of 12.5 mg; blister 14, box (box) 2; tablets of 12.5 mg; blister 14, box (box) 1; tablets of 25 mg; blister 7, box (box) 2; tablets of 25 mg; blister 14, box (box) 2; tablets of 25 mg; blister 14, box (box) 1; tablets of 12.5 mg; blister 7, pack cardboard 1; tablets of 25 mg; blister 7, pack cardboard 1.